A New Way to Treat Recurrent Clostridium difficile Infection
Who is Rebiotix?
Rebiotix is a results oriented biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome.
Our goal is to develop and widely distribute a new therapeutic product to treat recurrent Clostridium difficile infection (CDI).
Defeating Recurrent CDI
Reccurent CDI is a serious and growing health problem associated with antibiotic use and subsequent disturbance of the normal gut flora.
Restoration of the patient’s microbiota enables the patient’s flora to successfully compete against Clostridium difficile and stop the cycle of recurrence and on-going antimicrobial treatment.
In The News:
Fecal Transplant Superior to Vancomycin in Randomized Study
The results of the first randomized controlled study of fecal transplant (FT) demonstrated superiority compared with vancomycin for the treatment of recurrent Clostridium difficile infection (CDI).1 The results of the landmark FECAL trial were published in the New England Journal of Medicine in January 2013.
Of the 16 patients in the study who received a fecal transplant, 15 (94%) were cured of Clostridium difficile-associated diarrhea after either one or two fecal infusions.
Fecal Transplant Demonstrates High Efficacy in Single Center Study
Forty-nine patients with moderate to severe recurrent Clostridium difficile infection (CDI) who received a fecal transplant (FT) at the Henry Ford Health System, Detroit, MI, between May 2010 and 2011, recovered dramatically within 1-4 days.
There were no adverse events or documented recurrences with 100 days follow-up.
Patients Open to Fecal Microbiota Transplant
A majority of patients would choose to receive a fecal microbiota transplant (FMT) along with antibiotics for the treatment of recurrent Clostridium difficile infection (CDI), according to the results of a large scale survey administered to a convenience sample of outpatients at an academic medical center.
A total of 162 of the 191 survey respondents (85%) chose antibiotics followed by fecal reconstitution when presented with a hypothetical case of recurrent CDI which did not explicitly explain the fecal nature of the therapy.
Fecal Transplantation Is Associated with Increased Microbial Diversity
There was striking similarity in the gut microbial communities of patients with recurrent Clostridium difficile infection (CDI) following a successful fecal transplant (FT) in a pilot study using 16S rRNA gene sequencing analysis.